[go: up one dir, main page]

PL2726880T3 - Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty - Google Patents

Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty

Info

Publication number
PL2726880T3
PL2726880T3 PL12807837T PL12807837T PL2726880T3 PL 2726880 T3 PL2726880 T3 PL 2726880T3 PL 12807837 T PL12807837 T PL 12807837T PL 12807837 T PL12807837 T PL 12807837T PL 2726880 T3 PL2726880 T3 PL 2726880T3
Authority
PL
Poland
Prior art keywords
prostate cancer
prognosis
determining
treatment
cancer patients
Prior art date
Application number
PL12807837T
Other languages
English (en)
Inventor
Tommy Andersson
Anders BJARTELL
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of PL2726880T3 publication Critical patent/PL2726880T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL12807837T 2011-07-01 2012-06-28 Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty PL2726880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1150619 2011-07-01
PCT/SE2012/050738 WO2013006129A1 (en) 2011-07-01 2012-06-28 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
EP12807837.5A EP2726880B1 (en) 2011-07-01 2012-06-28 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients

Publications (1)

Publication Number Publication Date
PL2726880T3 true PL2726880T3 (pl) 2019-09-30

Family

ID=47437285

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12807837T PL2726880T3 (pl) 2011-07-01 2012-06-28 Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty

Country Status (8)

Country Link
US (1) US9278119B2 (pl)
EP (1) EP2726880B1 (pl)
DK (1) DK2726880T3 (pl)
ES (1) ES2735540T3 (pl)
HU (1) HUE045368T2 (pl)
PL (1) PL2726880T3 (pl)
TR (1) TR201910508T4 (pl)
WO (1) WO2013006129A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
CN111417403B (zh) * 2017-10-25 2024-06-04 温特研究公司 Wnt5a肽在减少癌症干细胞中的作用
WO2020053200A1 (en) * 2018-09-10 2020-03-19 Wntresearch Ab Peptides for use in treatment of psoriasis
CA3137093A1 (en) * 2019-04-16 2020-10-22 Wntresearch Ab Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601363B1 (fr) 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
WO1998023730A1 (en) * 1996-11-27 1998-06-04 The Penn State Research Foundation Compounds and methods for treating cancer
WO2000031261A2 (en) 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
EP1033405A3 (en) 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1226172A1 (en) 1999-11-05 2002-07-31 Forskarpatent i Syd AB Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
JP2003516390A (ja) 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2384763T3 (en) 2005-05-30 2015-07-20 Wntres Ab Peptide ligand for disrupting cancer cell migration
EP2280994A4 (en) * 2008-04-30 2011-05-25 Wntres Ab RESTORATION OF ESTROGEN RECEPTOR ACTIVITY
ES2527454T3 (es) 2008-08-13 2015-01-23 Wntresearch Ab El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
WO2012109540A1 (en) * 2011-02-10 2012-08-16 Fox Chase Cancer Center Methods for inducing epithelial cancer cell senescence

Also Published As

Publication number Publication date
EP2726880A4 (en) 2015-03-04
WO2013006129A1 (en) 2013-01-10
DK2726880T3 (da) 2019-07-15
US9278119B2 (en) 2016-03-08
EP2726880A1 (en) 2014-05-07
TR201910508T4 (tr) 2019-08-21
EP2726880B1 (en) 2019-04-17
US20140206623A1 (en) 2014-07-24
ES2735540T3 (es) 2019-12-19
HUE045368T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL233709A (en) A method to predict the likelihood of clinical outcome for a patient with prostate cancer
PT2619576T (pt) Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
IL237558A0 (en) Methods for treating locally advanced breast cancer
IL223189A0 (en) Methods of treatment of pancreatic cancer
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP2675485A4 (en) ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER
IL220788A (en) Factors associated with cancer treatment and method of preparation
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
ZA201205004B (en) Methods for treating pancreatic cancer
EP2643001A4 (en) METHOD OF TREATING CANCER
IL232493A0 (en) A method for quantifying cancer treatment
ZA201304225B (en) Methods of treating cancer
SI2742356T1 (sl) Prediktorji pri zdravljenju raka
IL228917A0 (en) Methods for treating solid tumors
EP2640390A4 (en) METHODS OF TREATING CANCER
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
ZA201306807B (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
PL2726880T3 (pl) Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty
EP2709730A4 (en) TREATMENT AND PROGNOSIS OF CANCER
EP2932273A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
EP2721410A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER
ZA201208905B (en) Cancer therapy method